Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Zenas BioPharma, Inc. (ZBIO)
Company Research
Source: GlobeNewswire
- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) - - Secured development and commercialization rights for three autoimmune product candidates, including orelabrutinib, a BTK Inhibitor in Phase 3 development for progressive forms of Multiple Sclerosis (MS) - - Entered into obexelimab funding agreement with Royalty Pharma for up to $300.0 million, including $75M upfront, to support clinical development and potential commercial launch - WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today reported financial results for the t
Show less
Read more
Impact Snapshot
Event Time:
ZBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZBIO alerts
High impacting Zenas BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
ZBIO
News
- Top SA Quant rated small-cap stocks as Russell 2000 notches a record close [Seeking Alpha]Seeking Alpha
- Zenas BioPharma (NASDAQ:ZBIO) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $55.00 price target on the stock.MarketBeat
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)PR Newswire
- Zenas BioPharma (NASDAQ:ZBIO) had its price target raised by analysts at Morgan Stanley from $34.00 to $37.00. They now have an "overweight" rating on the stock.MarketBeat
- Zenas BioPharma, Inc. GAAP EPS of -$1.22 [Seeking Alpha]Seeking Alpha
ZBIO
Earnings
- 11/12/25 - Miss
ZBIO
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- ZBIO's page on the SEC website